Will QC Allergy face new generic competition after 2025?

No, the primary compound patent for loratadine expired in 2000. Competition is already established and will continue from existing generic manufacturers and retailers.

Are there any pending patent applications that could impact QC Allergy's market?

While specific formulation or delivery method patents may exist, they are unlikely to impact the broad market for standard oral loratadine tablets due to their age and the availability of generic alternatives. The core therapeutic use is off-patent.

What is the average shelf life of QC Allergy tablets?

Typical shelf life for OTC oral medications like loratadine is 2-3 years from the date of manufacture, provided they are stored under recommended conditions. This information is usually printed on the product packaging.

How does QC Allergy's efficacy compare to branded Claritin?

As a generic product, QC Allergy is required to be bioequivalent to branded Claritin, meaning it contains the same active ingredient at the same dosage and is expected to have the same therapeutic effect.

Can QC Allergy be purchased with health savings accounts (HSAs) or flexible spending accounts (FSAs)?

Yes, as an over-the-counter medication for a recognized medical condition (allergy relief), QC Allergy is generally eligible for purchase with HSA/FSA funds. Consumers should verify specific plan details.

Pharmaceutical drug prices and trends for QC ALLERGY (LORAT)

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
QC ALLERGY (LORAT) 10 MG TAB	83324-0146-30	0.05231	EACH	2026-07-22
QC ALLERGY (LORAT) 10 MG TAB	83324-0147-10	0.05231	EACH	2026-07-22
QC ALLERGY (LORAT) 10 MG TAB	83324-0150-01	0.05231	EACH	2026-07-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for QC Allergy (Lorat), a non-sedating antihistamine. The analysis focuses on patent status, competitive landscape, generic entry, and market demand to forecast pricing trends through 2030.

What is the Current Market Status of QC Allergy (Lorat)?

QC Allergy, containing the active pharmaceutical ingredient loratadine, is an established over-the-counter (OTC) and prescription medication primarily used to treat allergy symptoms like sneezing, runny nose, itchy eyes, and hives. Loratadine is a second-generation H1 antagonist, known for its non-sedating profile compared to first-generation antihistamines.

The global allergy treatment market is substantial, driven by increasing prevalence of allergic rhinitis and other allergic conditions, heightened environmental pollution, and evolving lifestyles. Within this market, OTC antihistamines represent a significant segment due to their accessibility and self-treatment appeal.

Key Market Indicators:

Global Allergy Treatment Market Size: Estimated to be over \$25 billion in 2023, with a projected compound annual growth rate (CAGR) of 5-7% through 2030. [1]
Antihistamine Segment: Accounts for approximately 30-40% of the total allergy treatment market.
QC Allergy (Lorat) Positioning: As a generic or store-brand equivalent of prescription loratadine, QC Allergy competes in a price-sensitive segment. Its market presence is tied to its availability through various retail pharmacies, grocery stores, and online platforms.

What is the Patent Landscape for Loratadine?

Loratadine was originally developed by Schering-Plough and patented in the early 1980s. The primary compound patent for loratadine expired in the early 2000s, allowing for the widespread introduction of generic versions.

Original Patent Expiration: U.S. Patent No. 4,284,457 expired in 2000. [2]
Formulation Patents: While the core compound patent has expired, Schering-Plough and its successors may have held or currently hold patents on specific formulations, manufacturing processes, or novel uses of loratadine. However, the efficacy and safety of the basic loratadine molecule are well-established and largely off-patent.
Orange Book Listing: Loratadine is listed in the FDA's Orange Book, indicating approved drug products and their patent information. Most listed loratadine products are bioequivalent generics. [3]
Exclusivity Periods: Any remaining exclusivities related to specific formulations or indications would have largely expired or are nearing expiration, further facilitating generic competition.

The absence of strong, long-term patent protection for the core loratadine molecule is the primary driver of its generic market status.

Who are the Key Competitors for QC Allergy (Lorat)?

QC Allergy competes within the broader antihistamine market, which includes both prescription and OTC products. Its direct competitors are other generic loratadine products and other OTC second-generation antihistamines.

Direct Competitors (Generic Loratadine):

Claritin (Bayer): The original brand-name product. While QC Allergy is a generic competitor, Claritin maintains brand recognition and market share, often at a higher price point.
Store Brands: Numerous pharmacy chains (e.g., CVS, Walgreens, Rite Aid) and large retailers (e.g., Walmart, Target) offer their own generic loratadine products, often branded as "Allergy Relief" or similar. These are direct price competitors.
Other Generic Manufacturers: Companies like Teva, Mylan (now Viatris), and Sandoz manufacture and distribute generic loratadine under various labels and for different retail partners.

Indirect Competitors (Other OTC Antihistamines):

Cetirizine: Available as Zyrtec (McNeil Consumer Healthcare) and numerous generics. Cetirizine is also a second-generation antihistamine and a significant competitor to loratadine.
Fexofenadine: Available as Allegra (Sanofi) and generics. Fexofenadine is another non-sedating option that competes for market share.
Diphenhydramine and Chlorpheniramine: First-generation antihistamines (e.g., Benadryl, Chlor-Trimeton) are still available OTC but are generally less preferred due to their sedative effects. However, they represent a lower-cost alternative for some consumers.

The competitive landscape is characterized by intense price competition among generic manufacturers and retailers.

What is the Demand Outlook for QC Allergy (Lorat)?

Demand for QC Allergy is influenced by several factors:

Prevalence of Allergies: Rising rates of allergic rhinitis and other seasonal and perennial allergies continue to drive demand for effective treatment options. Factors contributing to this include increased environmental allergens, urbanization, and climate change.
Consumer Preference for OTC Medications: A strong preference for self-medication and accessible OTC treatments supports the demand for products like QC Allergy.
Non-Sedating Properties: The preference for non-sedating antihistamines remains high, particularly for individuals who need to remain alert during daily activities. This favors loratadine and its competitors over older, sedating options.
Price Sensitivity: As a generic product, QC Allergy's demand is also sensitive to price. Consumers often switch between generic loratadine products and other OTC antihistamines based on promotions and perceived value.
Seasonal Fluctuations: Demand typically peaks during allergy seasons (spring and fall in many regions) but remains consistent year-round due to perennial allergies.

Projected Demand Drivers:

Aging Population: Older adults may experience a higher incidence of certain allergic conditions.
Increased Air Pollution: Air pollutants can exacerbate allergic reactions, potentially increasing the need for antihistamines.
Consumer Education: Greater awareness of allergy symptoms and treatment options drives proactive purchasing.

The demand for loratadine generics, including QC Allergy, is expected to remain stable to moderately growing. The total market size for OTC antihistamines is projected to expand, with generic loratadine holding a significant, albeit competitive, share.

How is the Pricing of QC Allergy (Lorat) Determined?

The pricing of QC Allergy is primarily determined by the dynamics of the generic pharmaceutical market and retail pricing strategies.

Cost of Goods Sold (COGS): Manufacturing costs, raw material prices, and supply chain expenses are foundational.
Generic Competition: The presence of numerous generic manufacturers and private-label brands creates downward pressure on prices. Manufacturers compete aggressively on cost.
Retailer Markup: Pharmacies and retailers add their own markups, which vary based on their business model, target customer, and competitive positioning.
Promotional Pricing and Discounts: Retailers frequently offer discounts, loyalty program benefits, and bulk purchase incentives, which can significantly affect the perceived price for consumers.
Brand vs. Generic Pricing Differential: While QC Allergy is a generic, it may be priced slightly differently by various retailers compared to other generic loratadine products, aiming to capture market share. The price difference between generic loratadine and branded Claritin remains substantial.
Wholesale Acquisition Cost (WAC): This is the list price of a drug product from the manufacturer. Generic WACs are significantly lower than branded WACs.
Average Wholesale Price (AWP) & Maximum Allowable Cost (MAC): These are benchmarks used in the pharmaceutical industry and by payers to determine reimbursement and pricing limits for generic drugs.

Typical Pricing Structure (USD per typical package size, e.g., 30-count tablets):

Branded (Claritin): \$15 - \$25
Generic Loratadine (QC Allergy or similar store brands): \$5 - \$15
Value/Bulk Generic: \$3 - \$8

The price of QC Allergy will fluctuate based on the specific retailer, promotions, and package size.

What are the Price Projections for QC Allergy (Lorat) through 2030?

Given the mature status of loratadine and the highly competitive generic market, significant price increases for QC Allergy are unlikely. The trend is expected to be one of continued price stability with potential for slight declines driven by competition and retailer strategies.

Key Factors Influencing Future Pricing:

Sustained Generic Competition: The patent protection for loratadine has long expired. New generic entrants are unlikely, but the existing intense competition among manufacturers and retailers will persist.
Retailer Pricing Strategies: Retailers will continue to use generic antihistamines like QC Allergy as high-volume, low-margin products. Pricing will be strategic to drive foot traffic and overall basket size. Private-label brands are often priced aggressively to compete with or undercut other generics.
Therapeutic Alternatives: The availability of other effective and competitively priced OTC antihistamines (cetirizine, fexofenadine generics) will continue to exert pricing pressure.
Manufacturing Efficiency and COGS: While manufacturing efficiencies may slightly reduce costs, any significant shifts in raw material prices or global supply chain disruptions could introduce volatility, although unlikely to drive up prices substantially for such a mature product.
Demand Stability: Consistent demand for allergy relief, coupled with the accessible nature of loratadine, will ensure a stable market, preventing sharp price hikes based on scarcity.

Price Projection Trends (USD per typical 30-count package):

2024-2026: Expected to remain within the \$5 - \$15 range, with average prices likely at the lower end (\$5 - \$10) due to promotions and aggressive retailer pricing.
2027-2030: Projections indicate continued stability, with prices likely to average between \$4 - \$9. Minor fluctuations may occur based on specific retailer promotions or regional market dynamics. A significant upward trend is not anticipated.

Comparison to Branded Product: The price differential between QC Allergy and branded Claritin is expected to remain substantial, likely exceeding 50% and potentially reaching 80-90% depending on promotions.

The market for QC Allergy is mature, and its pricing will continue to be dictated by generic market forces and retail competition rather than patent expirations or new market entrants.

Key Takeaways

QC Allergy (Lorat) is a generic, non-sedating antihistamine with a mature market presence.
The core patent for loratadine expired in 2000, allowing for widespread generic competition.
The product competes directly with other generic loratadine products and indirectly with other OTC antihistamines like cetirizine and fexofenadine.
Demand is driven by increasing allergy prevalence, consumer preference for OTC treatments, and the non-sedating properties of loratadine.
Pricing is determined by generic market competition, retailer markups, and promotional activities, rather than manufacturing costs alone.
Price projections through 2030 indicate continued stability within the \$4 - \$15 range for typical package sizes, with a likelihood of prices settling towards the lower end of this spectrum. Significant price increases are not anticipated.

FAQs

Will QC Allergy face new generic competition after 2025? No, the primary compound patent for loratadine expired in 2000. Competition is already established and will continue from existing generic manufacturers and retailers.
Are there any pending patent applications that could impact QC Allergy's market? While specific formulation or delivery method patents may exist, they are unlikely to impact the broad market for standard oral loratadine tablets due to their age and the availability of generic alternatives. The core therapeutic use is off-patent.
What is the average shelf life of QC Allergy tablets? Typical shelf life for OTC oral medications like loratadine is 2-3 years from the date of manufacture, provided they are stored under recommended conditions. This information is usually printed on the product packaging.
How does QC Allergy's efficacy compare to branded Claritin? As a generic product, QC Allergy is required to be bioequivalent to branded Claritin, meaning it contains the same active ingredient at the same dosage and is expected to have the same therapeutic effect.
Can QC Allergy be purchased with health savings accounts (HSAs) or flexible spending accounts (FSAs)? Yes, as an over-the-counter medication for a recognized medical condition (allergy relief), QC Allergy is generally eligible for purchase with HSA/FSA funds. Consumers should verify specific plan details.

Citations

[1] Global Allergy Treatment Market Report. (n.d.). Statista. Retrieved from https://www.statista.com/outlook/30000000/100/allergy-treatment/worldwide (Note: Specific report access may require subscription. General market size data is publicly available.)

[2] U.S. Patent 4,284,457. (1981). Antihistaminic Compounds. Retrieved from Google Patents or USPTO database.

[3] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/drugod/ob/default.cfm

Drug Price Trends for QC ALLERGY (LORAT)

Average Pharmacy Cost for QC ALLERGY (LORAT)

QC Allergy (Lorat) Market Analysis and Price Projections